News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
AstraZeneca also played a critical role in the global response to COVID-19.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
Subscribe To Our Newsletter & Stay Updated
